<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Low-dose oral <z:chebi fb="0" ids="4911">etoposide</z:chebi> (50 mg for 10 to 14 days) and low-dose subcutaneous injection of <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (15-20 mg/12 hours for 14 to 17 days) (Et-A non i.v.) were given to refractory <z:hpo ids='HP_0011009'>acute</z:hpo> non-lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>Case 1 was a 47-year-old woman who had a relapsed M0 </plain></SENT>
<SENT sid="2" pm="."><plain>B-DOMP therapy failed but she recovered from severe <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>She had to go home to take care of her children </plain></SENT>
<SENT sid="4" pm="."><plain>Et-A non i.v. was given for 14 days and 11 mg of <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> was added on the 3rd day </plain></SENT>
<SENT sid="5" pm="."><plain>She achieved a complete remission (CR) </plain></SENT>
<SENT sid="6" pm="."><plain>Case 2 was a 72-year-old woman classified M4 </plain></SENT>
<SENT sid="7" pm="."><plain>Low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (Ara-C) with additional <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> (DNR) therapy failed </plain></SENT>
<SENT sid="8" pm="."><plain>She became weaker due to the gastrointestinal toxicity of DNR </plain></SENT>
<SENT sid="9" pm="."><plain>Et-A non i.v. was tried </plain></SENT>
<SENT sid="10" pm="."><plain>Oral <z:chebi fb="0" ids="4911">etoposide</z:chebi> (Et) for 10 days and Ara-C for 14 days proved effective, and she achieved CR </plain></SENT>
<SENT sid="11" pm="."><plain>Case 3 was a 59-year-old man with M4 developed from <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, complicated with <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Ara-C low-dose therapy was begun, but it was not effective </plain></SENT>
<SENT sid="13" pm="."><plain>It was switched to Et-A non i.v., 40 mg of DNR was added, with 12 mg of <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> and double administration of 3 mg of <z:chebi fb="0" ids="36373">vindesine</z:chebi> </plain></SENT>
<SENT sid="14" pm="."><plain>He also achieved CR </plain></SENT>
<SENT sid="15" pm="."><plain>Et-A non i.v. therapy is effective and available for induction therapy with low toxicity and convenient to daily life </plain></SENT>
</text></document>